European medicines agency grants atara biotherapeutics accelerated assessment of tab-cel® for the treatment of epstein-barr virus positive post-transplant lymphoproliferative disease (ptld)

South san francisco, calif.--(business wire)--atara biotherapeutics, inc. (nasdaq: atra), a pioneer in t-cell immunotherapy, leveraging its novel allogeneic ebv t-cell platform to develop transformative therapies for patients with cancer and autoimmune diseases, today announced the committee for medicinal products for human use (chmp) of the european medicines agency (ema) has granted accelerated assessment to the company's lead product candidate, tabelecleucel (tab-cel®), for the treatment of
ATRA Ratings Summary
ATRA Quant Ranking